This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Author: Avi Kapoor | November 19, 2024 12:21pm

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

BTIG analyst Julian Harrison upgraded the rating for Aclaris Therapeutics, Inc. (NASDAQ:ACRS) from Neutral to Buy and announced a price target of $8. Aclaris Therapeutics shares closed at $3.14 on Monday. See how other analysts view this stock.
HSBC analyst Wesley Brooks upgraded the rating for QuantumScape Corporation (NYSE:QS) from Reduce to Hold and announced a price target of $5.3. QuantumScape shares closed at $4.73 on Monday. See how other analysts view this stock.
Evercore ISI Group analyst Cory Kasimov upgraded the rating for BioNTech SE (NASDAQ:BNTX) from In-Line to Outperform and boosted the price target from $110 to $125. BioNTech shares closed at $101.87 on Monday. See how other analysts view this stock.
Canaccord Genuity analyst Matthew Lee upgraded Bank of Nova Scotia (TSX:BNS) from Hold to Buy and raised the price target from C$71 to C$84. See how other analysts view this stock.
Jefferies analyst Roger Song upgraded the rating for Aclaris Therapeutics, Inc. (NASDAQ:ACRS) from Hold to Buy and raised the price target from $2 to $7. Aclaris Therapeutics shares closed at $3.14 on Monday. See how other analysts view this stock.